Search Results

You are looking at 11 - 20 of 1,139 items for :

Clear All
Full access

Alfredo A. Santillan, Jeffrey M. Farma, Kenneth L. Meredith, Nilay R. Shah and Scott T. Kelley

, 2007 . CA Cancer J Clin 2007 ; 57 : 43 – 66 . 3. Kelsen DP Ginsberg R Pajak TF . Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer . N Engl J Med 1998 ; 339 : 1979 – 1984 . 4

Full access

Stephen B. Edge

clinical trials. Early trials showed that extended surgery (“local therapy”) does not improve mortality over less aggressive surgery. Trials conducted in the 1970s and 1980s clearly showed that radical surgery involving removal of the breast provides no

Full access

Caijin Lin, Jiayi Wu, Shuning Ding, Chihwan Goh, Lisa Andriani, Shuangshuang Lu, Kunwei Shen and Li Zhu

– 11 De novo MBC is considered incurable but treatable. Generally, systemic therapy is viewed as the mainstay of treatment. 12 Primary tumor surgery is considered in selected patients, mostly in the palliative setting for those with impending

Full access

Mark D. Tyson and Sam S. Chang

salvage therapies. 7 Although most recurrences present within the first couple of years after surgery and approximately half of all distant recurrences occur in the lung, late recurrences and nonpulmonary sites of metastatic disease are not uncommon. 5

Full access

Mark T. Wakabayashi, Paul S. Lin and Amy A. Hakim

Edited by Kerrin G. Robinson

debulking surgery . J Surg Oncol 1991 ; 48 : 39 – 44 . 4. McGuire WP Hoskins WJ Brady MF . Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer . N Engl J Med 1996

Full access

Matthew D. Galsky, Harry W. Herr and Dean F. Bajorin

: 3020 – 3028 . 4 Herr HW : Surgical factors in bladder cancer: more (nodes) + more (pathology) = less (mortality) . BJU Int 2003 ; 92 : 187 – 188 . 5 Herr HW : Extent of surgery and pathology evaluation has an impact on bladder

Full access

Ernest S. Han and Mark Wakabayashi

Advanced-stage disease (stage III–IV) is diagnosed in 75% to 85% of patients, and standard management generally involves cytoreductive surgery and platinum/taxane-based chemotherapy. 2 Novel strategies and technologies are desperately needed to diagnose

Full access

Meaghan Tenney and Joan L. Walker

Gynecologic Oncology Group study (LAP2) . J Clin Oncol 2009 ( submitted ). 22 Malur S Possover M Michels W Schneider A . Laparoscopic-assisted vaginal versus abdominal surgery in patients with endometrial cancer--a prospective randomized trial

Full access

Prajnan Das, Norio Fukami and Jaffer A. Ajani

comparison with previous meta-analyses . Tumori 2002 ; 88 : 21 – 27 . 35. Macdonald JS Smalley SR Benedetti J . Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction . N Engl

Full access

Grant A. McArthur

. Fiore M Miceli R Mussi C . Dermatofibrosarcoma protuberans treated at a single institution: a surgical disease with a high cure rate . J Clin Oncol 2005 ; 23 : 7669 – 7675 . 4. Chang CK Jacobs IA Salti GI . Outcomes of surgery for